Understanding and targeting treatment resistance in a specific type of prostate cancer
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-11056736
This study is looking at how changes in the SPOP gene might make prostate cancer harder to treat, especially when standard treatments aren't working, and it aims to find new ways to help patients with this tough-to-treat cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11056736 on ClinicalTrials.gov |
What this research studies
This research investigates how certain mutations in the SPOP gene contribute to treatment resistance in prostate cancer, particularly in cases where traditional therapies fail. The study aims to uncover the mechanisms behind this resistance, focusing on the interaction between SPOP mutations and the MAPK signaling pathway. By examining these interactions in laboratory models, the researchers hope to identify new therapeutic strategies that could improve treatment outcomes for patients with castration-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer that has mutations in the SPOP gene and who are experiencing resistance to standard androgen receptor inhibitors.
Not a fit: Patients with prostate cancer that does not involve SPOP mutations or those who are not resistant to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with SPOP-mutated prostate cancer who currently have limited options.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOU, ZHENKUN — MAYO CLINIC ROCHESTER
- Study coordinator: LOU, ZHENKUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer